JP2015516578A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015516578A5 JP2015516578A5 JP2015512143A JP2015512143A JP2015516578A5 JP 2015516578 A5 JP2015516578 A5 JP 2015516578A5 JP 2015512143 A JP2015512143 A JP 2015512143A JP 2015512143 A JP2015512143 A JP 2015512143A JP 2015516578 A5 JP2015516578 A5 JP 2015516578A5
- Authority
- JP
- Japan
- Prior art keywords
- cholesten
- composition
- dihydroxy
- cholestan
- labeled
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012491 analyte Substances 0.000 claims description 19
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims description 15
- 239000003613 bile acid Substances 0.000 claims description 15
- 239000002243 precursor Substances 0.000 claims description 15
- 239000003153 chemical reaction reagent Substances 0.000 claims description 12
- UQPYXHJTHPHOMM-NIBOIBLTSA-N 7alpha,12alpha-dihydroxycholest-4-en-3-one Chemical compound C([C@H]1O)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)[C@@H](O)C2 UQPYXHJTHPHOMM-NIBOIBLTSA-N 0.000 claims description 10
- PESKGJQREUXSRR-UXIWKSIVSA-N 5alpha-cholestan-3-one Chemical compound C([C@@H]1CC2)C(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 PESKGJQREUXSRR-UXIWKSIVSA-N 0.000 claims description 8
- PESKGJQREUXSRR-UHFFFAOYSA-N 5beta-cholestanone Natural products C1CC2CC(=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 PESKGJQREUXSRR-UHFFFAOYSA-N 0.000 claims description 8
- NYOXRYYXRWJDKP-GYKMGIIDSA-N cholest-4-en-3-one Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 NYOXRYYXRWJDKP-GYKMGIIDSA-N 0.000 claims description 8
- NYOXRYYXRWJDKP-UHFFFAOYSA-N cholestenone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 NYOXRYYXRWJDKP-UHFFFAOYSA-N 0.000 claims description 8
- 230000007812 deficiency Effects 0.000 claims description 8
- 150000002500 ions Chemical group 0.000 claims description 8
- 238000002372 labelling Methods 0.000 claims description 7
- 101000875401 Homo sapiens Sterol 26-hydroxylase, mitochondrial Proteins 0.000 claims description 6
- 102100036325 Sterol 26-hydroxylase, mitochondrial Human genes 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 239000011159 matrix material Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- HHVQPBXBALLUDF-QORHGLQKSA-N 7alpha,12alpha-dihydroxy-5beta-cholestan-3-one Chemical compound C([C@H]1C[C@H]2O)C(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)[C@@H](O)C1 HHVQPBXBALLUDF-QORHGLQKSA-N 0.000 claims description 4
- HWOOALPDOJHOPO-YREUSXKVSA-N 7alpha-hydroxy-5beta-cholestan-3-one Chemical compound C([C@H]1C[C@H]2O)C(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 HWOOALPDOJHOPO-YREUSXKVSA-N 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 150000001450 anions Chemical group 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 238000004949 mass spectrometry Methods 0.000 claims description 4
- 238000001212 derivatisation Methods 0.000 claims description 3
- 108090000854 Oxidoreductases Proteins 0.000 claims description 2
- 206010048215 Xanthomatosis Diseases 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 230000002490 cerebral effect Effects 0.000 claims description 2
- 150000004677 hydrates Chemical class 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 210000002435 tendon Anatomy 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 18
- 238000004458 analytical method Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 20
- 239000000090 biomarker Substances 0.000 description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 description 3
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261649044P | 2012-05-18 | 2012-05-18 | |
| US61/649,044 | 2012-05-18 | ||
| PCT/IB2013/000961 WO2013171568A1 (en) | 2012-05-18 | 2013-05-17 | Analysis of a panel of cerebrotendinous xanthomatosis biomarkers using site specific derivation and lc/ms/ms workflow |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015516578A JP2015516578A (ja) | 2015-06-11 |
| JP2015516578A5 true JP2015516578A5 (enExample) | 2016-07-07 |
| JP6272834B2 JP6272834B2 (ja) | 2018-01-31 |
Family
ID=49583216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015512143A Expired - Fee Related JP6272834B2 (ja) | 2012-05-18 | 2013-05-17 | サイト特異的誘導とｌｃ／ｍｓ／ｍｓワークフローとを使用した脳腱黄色腫症バイオマーカーのパネルの解析 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10078091B2 (enExample) |
| EP (1) | EP2850430B1 (enExample) |
| JP (1) | JP6272834B2 (enExample) |
| CN (1) | CN104603617B (enExample) |
| CA (1) | CA2873650A1 (enExample) |
| WO (1) | WO2013171568A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104040343A (zh) * | 2012-01-05 | 2014-09-10 | Dh科技发展私人贸易有限公司 | 增强含有酮类固醇和酮基或醛的分析物的灵敏度和特异性 |
| CN105785048B (zh) * | 2016-04-15 | 2017-07-28 | 同济大学 | 基于轻同位素近同重标记的整体蛋白质定量分析方法 |
| CN105866429B (zh) * | 2016-05-06 | 2017-12-15 | 同济大学 | 基于自带电荷同位素试剂的生物分子标记和定量分析方法 |
| EP3826994A1 (en) * | 2018-07-24 | 2021-06-02 | F. Hoffmann-La Roche AG | Reagent for mass spectrometry |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3029907B2 (ja) * | 1991-12-20 | 2000-04-10 | 理化学研究所 | 抗肥満剤 |
| US7799576B2 (en) | 2003-01-30 | 2010-09-21 | Dh Technologies Development Pte. Ltd. | Isobaric labels for mass spectrometric analysis of peptides and method thereof |
| US20050148771A1 (en) | 2004-01-05 | 2005-07-07 | Applera Corporation. | Active esters of N-substituted piperazine acetic acids, including isotopically enriched versions thereof |
| US20060183238A1 (en) | 2005-02-09 | 2006-08-17 | Applera Corporation | Amine-containing compound analysis methods |
| EP2054540B1 (en) | 2006-05-26 | 2014-11-26 | DH Technologies Development Pte. Ltd. | Tagging reagents and methods for hydroxylated compounds |
| GB0713463D0 (en) * | 2007-07-11 | 2007-08-22 | Btg Int Ltd | Modulators of hypoxia inducible factor-1 and related uses |
| US8158435B2 (en) * | 2007-05-04 | 2012-04-17 | Oregon Health & Science University | Tandem mass spectrometry for detecting and/or screening for conditions associated with altered sterols |
| WO2010141075A1 (en) * | 2009-05-31 | 2010-12-09 | Dh Technologies Development Pte. Ltd. | Specific analysis of ketone and aldehyde analytes using reagent compounds labeling strategies, and mass spectrometry workflow |
| US8372653B2 (en) | 2010-01-22 | 2013-02-12 | Dh Technologies Development Pte. Ltd. | Mass tag reagents for simultaneous quantitation and identification of small molecules |
-
2013
- 2013-05-17 EP EP13791312.5A patent/EP2850430B1/en not_active Not-in-force
- 2013-05-17 JP JP2015512143A patent/JP6272834B2/ja not_active Expired - Fee Related
- 2013-05-17 CN CN201380026048.3A patent/CN104603617B/zh not_active Expired - Fee Related
- 2013-05-17 WO PCT/IB2013/000961 patent/WO2013171568A1/en not_active Ceased
- 2013-05-17 CA CA2873650A patent/CA2873650A1/en not_active Abandoned
- 2013-05-17 US US14/401,427 patent/US10078091B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Greco et al. | Applications of MALDI-TOF mass spectrometry in clinical proteomics | |
| Guo et al. | Probing gender-specific lipid metabolites and diagnostic biomarkers for lung cancer using Fourier transform ion cyclotron resonance mass spectrometry | |
| JP2012529010A5 (enExample) | ||
| CA2482173A1 (en) | Method for detecting low concentrations of a target bacterium that uses phages to infect target bacterial cells | |
| US20170097355A1 (en) | Biomarkers and methods to distinguish ovarian cancer from benign tumors | |
| US9146219B2 (en) | Sensitive method for measuring cis-diol containing compounds in plasma using 2D-LC-MS/MS | |
| Xiong et al. | DNA hydroxymethylation age of human blood determined by capillary hydrophilic-interaction liquid chromatography/mass spectrometry | |
| Vreeker et al. | Dried blood spot N-glycome analysis by MALDI mass spectrometry | |
| JP2015516578A5 (enExample) | ||
| Zhou et al. | A dual amplification strategy for DNA detection combining bio-barcode assay and metal-enhanced fluorescence modality | |
| Wang et al. | Quantification of free sialic acid in human plasma through a robust quinoxalinone derivatization and LC–MS/MS using isotope-labeled standard calibration | |
| Song et al. | Quantitative MALDI-MS assay of steroid hormones in plasma based on hydroxylamine derivatization | |
| Hsu et al. | Urinary exposure marker discovery for toxicants using ultra-high pressure liquid chromatography coupled with Orbitrap high resolution mass spectrometry and three untargeted metabolomics approaches | |
| CN107085061A (zh) | 基于hplc‑ms/ms检测平台的溶血磷脂酰胆碱的绝对定量分析方法 | |
| Wagner et al. | Metabolite structure analysis by high-resolution MS: supporting drug-development studies | |
| US10837972B2 (en) | Mass spectrometric determination of derivatized methylmalonic acid | |
| CN113484404A (zh) | 一种金属有机框架材料的制备方法及其小分子检测应用 | |
| JP2013076629A (ja) | α２，６−シアロ糖鎖とα２，３−シアロ糖鎖とを識別する方法 | |
| JP6272834B2 (ja) | サイト特異的誘導とｌｃ／ｍｓ／ｍｓワークフローとを使用した脳腱黄色腫症バイオマーカーのパネルの解析 | |
| JP2016539322A (ja) | アミノピラゾールを使用するカテコールアミンのマススペクトロメトリーによる同定および／または定量 | |
| CN112379009A (zh) | 生物样本中类固醇激素的检测方法及该方法所用试剂盒 | |
| Zhang et al. | Validation and quantification of genomic 5-carboxylcytosine (5caC) in mouse brain tissue by liquid chromatography-tandem mass spectrometry | |
| WO2015044958A1 (en) | Quantitation of structural isomers using maldi ms/ms | |
| WO2023205248A1 (en) | Multiplexing homocysteine and cysteine in first-tier screening assays | |
| CN115754062A (zh) | 一种甲硫氨酸循环关键代谢物的绝对定量分析方法及应用 |